Answers are grounded in this paper and cite their sources.
Current guidelines recommend the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), especially in patients with comorbid diabetes and obesity. This study investigated the effects of GLP-1RAs on hepatic steatosis and fibrosis in patients with MASLD, as measured by changes in vibration-controlled transient elastography (VCTE) and other clinical parameters in a real-world clinical setting.
No takes yet. Share an insight, caveat, or question.
Akhverdyan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: